News ArticleRail Vikas Nigam Limited to Approve Q2 and H1 FY2026-27 Unaudited Financial Results on November 13, 2026
Trading window closure period from October 1 to November 15, 2026, coinciding with the financial results announcement
Rail Vikas Nigam Limited (RVNL) announced a Board Meeting on November 13, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with trading window closure from October 1 to November 15, 2026.
Rail Vikas Nigam Limited
General / Other
Rail Vikas Nigam Limited (RVNL) has scheduled a Board Meeting on November 13, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
The financial results will be reviewed beforehand by the Audit Committee as per the listing regulations.
RVNL has initiated a trading window closure period starting from October 1, 2026, which will continue until November 15, 2026, to prevent insiders from dealing in company shares during the sensitive period around the financial results announcement.
This trading window closure is in accordance with RVNL's code of conduct for designated persons and their immediate relatives.
The closure period ensures compliance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Highlights
- Board Meeting set for November 13, 2026, to approve Q2 and H1 FY2026-27 financial results.
- Unaudited standalone and consolidated results for the periods ending September 30, 2026, will be considered.
- Trading window closure effective from October 1, 2026, through November 15, 2026.
- Audit Committee to review financial results prior to Board approval.
Key Data Snapshot
What happened
- Rail Vikas Nigam Limited has scheduled a Board Meeting on November 13, 2026.
- The Board will consider and approve unaudited financial results for the quarter and half year ended September 30, 2026.
- The financial results include both standalone and consolidated figures.
Key details
- The financial results will be reviewed by the Audit Committee before Board approval.
- Trading window closure started on October 1, 2026, and will end on November 15, 2026, 48 hours after the financial results declaration.
- Insiders are advised not to trade in the company's shares during the closure period to comply with company regulations.
Regulatory and governance context
- The notification complies with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Trading window closure is as per RVNL's code of conduct for designated persons and their immediate relatives.
- Prior notice of trading window closure was given on September 25, 2026.
Highlights
- Board Meeting set for November 13, 2026, to approve Q2 and H1 FY2026-27 financial results.
- Unaudited standalone and consolidated results for the periods ending September 30, 2026, will be considered.
- Trading window closure effective from October 1, 2026, through November 15, 2026.
- Audit Committee to review financial results prior to Board approval.
Disclosures
- Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
